Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 2, 2012, Pages 200-212

  Wozniak, Antoinette ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis inhibitor; Biological marker; Carcinoma; Non small cell lung; Protein tyrosine kinase; Receptor; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; AV 0005; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC THERAPY; ASTHENIA; BLEEDING; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLIOBLASTOMA; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE K RAS; OVARY CANCER; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEINURIA; RECURRENCE RISK; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SMOOTH MUSCLE FIBER; STOMACH CANCER; STOMATITIS; TUMOR VASCULARIZATION; VASCULAR SMOOTH MUSCLE CELL;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 84859426342     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.05.003     Document Type: Review

References (104)

1. World Health Organization. Fact Sheet No. 310: The top ten causes of death. November 2008. Accessed October 8; 2009. http://www.who.int/mediacentre/factsheets/fs310_2008.pdf.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. American Cancer Society Cancer facts & figures, 2009 2009, American Cancer Society, Inc., Atlanta, GA.
4. Ramalingam S., Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008, 13(Suppl. 1):5-13.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer. V.2.2010. Accessed April 8; 2010. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
6. Scagliotti G.V., Parikh P., von Pawel J., et al. study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
7. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
8. Breathnach O.S., Freidlin B., Conley B., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
9. Tarceva® (erlotinib tablets) [package insert]. South San Franscisco, CA: Genentech, Inc.
10. AstraZeneca. IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe. Accessed April 8; 2010. http://www.astrazeneca.com/Media/Press-releases/Article/20090701--IRESSA-Gefitinib-Receives-Marketing-Authorisation-f.
11. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
12. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
13. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
14. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
15. Folkman J., Klagsbrun M. Vascular physiology A family of angiogenic peptides. Nature 1987, 329:671-672.
16. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
17. Fukumura D., Xavier R., Sugiura T., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94:715-725.
18. Gerber H.P., Kowalski J., Sherman D., Eberhard D.A., Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000, 60:6253-6258.
19. Toi M., Matsumoto T., Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001, 2:667-673.
20. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
21. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
22. Sund M., Hamano Y., Sugimoto H., et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005, 102:2934-2939.
23. Yuan A., Yu C.-J., Kuo S.-H., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001, 19:432-441.
24. Millauer B., Longhi M.P., Plate K.H., et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56:1615-1620.
25. Alvarez R.H., Kantarjian H.M., Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006, 81:1241-1257.
26. Bergsten E., Uutela M., Li X., et al. PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor. Nat Cell Biol 2001, 3:512-516.
27. Wu E., Palmer N., Tian Z., et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008, 3:e3794.
28. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004, 15:229-235.
29. Beitz J.G., Kim I.S., Calabresi P., Frackelton Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci USA 1991, 88:2021-2025.
30. Pietras K., Rubin K., Sjoblom T., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62:5476-5484.
31. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
32. Hellstrom M., Gerhardt H., Kalen M., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001, 153:543-553.
33. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003, 112:1142-1151.
34. Hellstrom M., Kalen M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
35. Jain R.K., Booth M.F. What brings pericytes to tumor vessels?. J Clin Invest 2003, 112:1134-1136.
36. Dong J., Grunstein J., Tejada M., et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004, 23:2800-2810.
37. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
38. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
39. Cabebe E., Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007, 8:15-27.
40. Murakami M., Zheng Y., Hirashima M., et al. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler Thromb Vasc Biol 2008, 28:658-664.
41. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
42. Rusnati M., Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 2007, 13:2025-2044.
43. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
44. Kano M.R., Morishita Y., Iwata C., et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005, 118:3759-3768.
45. Nissen L.J., Cao R., Hedlund E.M., et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007, 117:2766-2777.
46. Avastin® (bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2009.
47. Reynolds S. National Cancer Institute. FDA Advisory Committee Recommends against Bevacizumab for Metastatic Breast Cancer. Accessed September 9; 2010. http://www.cancer.gov/ncicancerbulletin/072710/page2.
48. Genentech. Genentech provides update on Avastin for metastatic breast cancer following reviews in Europe and the United States. Accessed December 16; 2010. http://www.gene.com/gene/news/press-releases/display.do%3Fmethod=detail%26id=13127.
49. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
50. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
51. Reck M., von Pawel J., Zatloukal P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
52. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234.
53. Genentech Inc. Synopsis of Clinical Study Report. A pilot study of the bevacizumab plus carboplatin and paclitaxel in subjects with advanced, previously untreated, squamous non-small cell lung cancer; 2010.
54. Socinski M.A., Langer C.J., Huang J.E., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27:5255-5261.
55. Herbst R.S. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006, 8:S23-S30.
56. Fischbach N.A., Spigel D., Brahmer J., et al. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: a bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol 2009, 27. [abstract 8040].
57. Wozniak A.J., Garst J., Jahanzeb M., et al. Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J Clin Oncol 2010, 28. [abstract 7618].
58. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008, 26:60-65.
59. Leighl N.B., Zatloukal P., Mezger J., et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010, 5:1970-1976.
60. Miller V.A., O'Conner P., Soh C., Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27:LBA8002.
61. Kabbinavar F.F., Miller V.A., Johnson B.E., O'Connor P.G., Soh C., Tlas I. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28. [abstract 7526].
62. ®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA) [plenary abstract]. J Thorac Oncol 2008, 3:S302. [abstract 189].
63. Patel J.D., Bonomi P., Socinski M.A., et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009, 10:252-256.
64. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008, 14:6371-6375.
65. Ellis L.M., Hicklin D.J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009, 15:7471-7478.
66. Lockhart A.C., Rothenberg M.L., Dupont J., et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010, 28:207-214.
67. Leighl N.B., Raez L.E., Besse B., et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010, 5:1054-1059.
68. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
69. NEXAVAR (sorafenib) tablets, oral [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2009.
70. Schiller J.H., Lee J.W., Hanna N.H., Traynor A.M., Carbone D.P. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008, 26. [abstract 8014].
71. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
72. Bayer Healthcare Pharmaceuticals Inc., Onyx Pharmaceuticals Inc. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival. Press release. June 14; 2010. Accessed July 27; 2010. http://www.onyx-pharm.com/view.cfm/685/Phase-3-Trial-of-Nexavar-in-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-Does-Not-Meet-Primary-Endpoint-of-Overall-Survival.
73. Sun L., Liang C., Shirazian S., et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003, 46:1116-1119.
74. SUTENT® (sunitinib malate) capsules, oral [package insert]. New York, NY: Pfizer Inc.; 2010.
75. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:650-656.
76. Novello S., Scagliotti G.V., Rosell R., et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009, 101:1543-1548.
77. Roth G.J., Heckel A., Colbatzky F., et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009, 52:4466-4480.
78. Hilberg F., Roth G.J., Krssak M., et al. BIBF 1120 triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
79. Ellis P.M., Kaiser R., Zhao Y., Stopfer P., Gyorffy S., Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010, 16:2881-2889.
80. Reck M., Kaiser R., Eschbach C., et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011, [Epub, January 6].
81. Schiller J.H., Larson T., Ou S.H., et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009, 27:3836-3841.
82. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 2010, 28:49-55.
83. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
84. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006, 66:8715-8721.
85. Amgen. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-squamous NSCLC Patients in the Motesanib MONET1 Trial. Accessed May 12; 2010. http://www.amgen.com/media/media_pr_detail.jsp%3Fyear=2009%26releaseID=1255738.
86. Choueiri T.K. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008, 9:658-671.
87. Kumar R., Knick V.B., Rudolph S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6:2012-2021.
88. Podar K., Tonon G., Sattler M., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006, 103:19478-19483.
89. Altorki N., Lane M.E., Bauer T., et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010, 28:3131-3137.
90. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
91. Natale R.B., Thongprasert S., Greco F.A., et al. Phase III Trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011, [Epub, January 31].
92. De Boer R.H., Arrieta O., Yang C.H., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, [Epub, January 31].
93. Herbst R.S., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
94. Lee J., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28. [abstract 7525].
95. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008, 14:1407-1412.
96. Hanrahan E.O., Ryan A.J., Mann H., et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009, 15:3600-3609.
97. Hanrahan E.O., Lin H.Y., Kim E.S., et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010, 28:193-201.
98. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
99. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
100. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007, 104:17069-17074.
101. Kim E.S., Herbst R.S., Lee J.J., et al. The BATTLE trial (biomarker-integrated approaches of targeted therapy for lung cancer elimination): personalizing therapy for lung cancer. Presented at: the 101st annual meeting of the American Association for cancer research 2010.
102. Herbst R.S., Blumenschein G.R., Kim E.S., et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol (Meeting Abstracts) 2010, 28:7609.
103. Dahlberg S.E., Sandler A.B., Brahmer J.R., Schiller J.H., Johnson D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010, 28:949-954.
104. Hurwitz H., Douglas P.S., Middleton J.P., et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 2010, 28. [abstract 3039].